{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T08:23:10Z","timestamp":1784794990902,"version":"3.55.0"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,10,29]]},"DOI":"10.7759\/cureus.72595","type":"journal-article","created":{"date-parts":[[2024,10,29]],"date-time":"2024-10-29T07:02:22Z","timestamp":1730185342000},"source":"Crossref","is-referenced-by-count":2,"title":["Evaluating the Efficacy and Cost-Effectiveness of Plasmapheresis and Intravenous Immunoglobulin in Acute Guillain-Barre Syndrome Management in Emergency Departments"],"prefix":"10.7759","author":[{"given":"Waseem","family":"Ullah","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haider","family":"Ali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasir","family":"Muhammad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naqeeb","family":"Ullah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iqra","family":"Khalil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sohail","family":"Ahmad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Obaid","family":"Ullah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amjad","family":"Ali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad Younas","family":"Ali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Awais","family":"Manan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sundas","family":"Safdar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanifullah","family":"Hanfi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","article-title":"Guillain-Barr\u00e9 syndrome","volume":"87","author":"Walling AD","year":"2013","unstructured":"Walling AD, Dickson G. Guillain-Barr\u00e9 syndrome. Am Fam Phys. 2013, 87:191-7.","journal-title":"Am Fam Phys"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1212\/CON.0000000000000513","article-title":"Guillain-Barr\u00e9 Syndrome","volume":"23","author":"Donofrio PD","year":"2017","unstructured":"Donofrio PD. Guillain-Barr\u00e9 Syndrome. Continuum (Minneap Minn). 2017, 23:1295-309. 10.1212\/CON.0000000000000513","journal-title":"Continuum (Minneap Minn)"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000038890","article-title":"Clinical presentation and symptomatology of Guillain-Barr\u00e9 syndrome: a literature review","volume":"103","author":"Elendu C","year":"2024","unstructured":"Elendu C, Osamuyi EI, Afolayan IA, et al.. Clinical presentation and symptomatology of Guillain-Barr\u00e9 syndrome: a literature review. Medicine (Baltimore). 2024, 103:e38890. 10.1097\/MD.0000000000038890","journal-title":"Medicine (Baltimore)"},{"key":"ref4","article-title":"Treatment options for Guillain-Barre syndrome (GBS) - a comparative assessment of treatment efficacy between intravenous immune globulin (IVIG) with plasmaphoresis","volume":"61","author":"Muhammad WW","year":"2011","unstructured":"Muhammad WW, Yousaf MA, Ullah MU, Khan AM, Yousaf MJ, Qadir M. Treatment options for Guillain-Barre syndrome (GBS) - a comparative assessment of treatment efficacy between intravenous immune globulin (IVIG) with plasmaphoresis. Pak Armed Forces Med J. 2011, 61:282-5.","journal-title":"Pak Armed Forces Med J"},{"key":"ref5","doi-asserted-by":"crossref","DOI":"10.1016\/j.jval.2017.08.2113","article-title":"Cost-effectiveness analysis of 10% intravenous immunoglobulin compared with plasma exchange in treatment of children with Guillain-Barr\u00e9 syndrome in Russia","volume":"20","author":"Ugrekhelidze D","year":"2017","unstructured":"Ugrekhelidze D, Yagudina R, Kulikov A. Cost-effectiveness analysis of 10% intravenous immunoglobulin compared with plasma exchange in treatment of children with Guillain-Barr\u00e9 syndrome in Russia. Value Health. 2017, 20:A753.","journal-title":"Value Health"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.4103\/0973-6247.187940","article-title":"Reducing the economic burden in management of Guillain-Barre syndrome using modified plasmapheresis","volume":"10","author":"Iyer RR","year":"2016","unstructured":"Iyer RR, Shah PH, Roy SS, Suri SK. Reducing the economic burden in management of Guillain-Barre syndrome using modified plasmapheresis. Asian J Transfus Sci. 2016, 10:118-21. 10.4103\/0973-6247.187940","journal-title":"Asian J Transfus Sci"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.3233\/NRE-201640","article-title":"Functional outcomes following inpatient rehabilitation of Guillain-Barr\u00e9 syndrome patients: intravenous immunoglobulins versus plasma exchange","volume":"48","author":"Bondi M","year":"2021","unstructured":"Bondi M, Engel-Haber E, Wolff J, Grosman-Rimon L, Bloch A, Zeilig G. Functional outcomes following inpatient rehabilitation of Guillain-Barr\u00e9 syndrome patients: intravenous immunoglobulins versus plasma exchange. NeuroRehabilitation. 2021, 48:543-51. 10.3233\/NRE-201640","journal-title":"NeuroRehabilitation"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaip.2023.04.002","article-title":"Intravenous immunoglobulin: mechanism of action in autoimmune and inflammatory conditions","volume":"11","author":"Bayry J","year":"2023","unstructured":"Bayry J, Ahmed EA, Toscano-Rivero D, et al.. Intravenous immunoglobulin: mechanism of action in autoimmune and inflammatory conditions. J Allergy Clin Immunol Pract. 2023, 11:1688-97. 10.1016\/j.jaip.2023.04.002","journal-title":"J Allergy Clin Immunol Pract"},{"key":"ref9","article-title":"The efficacy of intravenous immunoglobulin in Guillain-Barr\u00e9 syndrome: the experience of a tertiary medical center","volume":"20","author":"Shalem D","year":"2018","unstructured":"Shalem D, Shemer A, Shovman O, Shoenfeld Y, Kivity S. The efficacy of intravenous immunoglobulin in Guillain-Barr\u00e9 syndrome: the experience of a tertiary medical center. Isr Med Assoc J. 2018, 20:754-60.","journal-title":"Isr Med Assoc J"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.608130","article-title":"Intensive care and treatment of severe Guillain-Barr\u00e9 syndrome","volume":"12","author":"Shang P","year":"2021","unstructured":"Shang P, Feng J, Wu W, Zhang HL. Intensive care and treatment of severe Guillain-Barr\u00e9 syndrome. Front Pharmacol. 2021, 12:608130. 10.3389\/fphar.2021.608130","journal-title":"Front Pharmacol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1097\/CND.0b013e3181f3dbbf","article-title":"Plasma exchange after initial intravenous immunoglobulin treatment in Guillain-Barr\u00e9 syndrome: critical reassessment of effectiveness and cost-efficiency","volume":"12","author":"Oczko-Walker M","year":"2010","unstructured":"Oczko-Walker M, Manousakis G, Wang S, Malter JS, Waclawik AJ. Plasma exchange after initial intravenous immunoglobulin treatment in Guillain-Barr\u00e9 syndrome: critical reassessment of effectiveness and cost-efficiency. J Clin Neuromuscul Dis. 2010, 12:55-61. 10.1097\/CND.0b013e3181f3dbbf","journal-title":"J Clin Neuromuscul Dis"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1093\/immadv\/ltac012","article-title":"Plasma exchange for severe immune-related adverse events from checkpoint inhibitors: an early window of opportunity?","volume":"2","author":"Katsumoto TR","year":"2022","unstructured":"Katsumoto TR, Wilson KL, Giri VK, et al.. Plasma exchange for severe immune-related adverse events from checkpoint inhibitors: an early window of opportunity?. Immunother Adv. 2022, 2:ltac012. 10.1093\/immadv\/ltac012","journal-title":"Immunother Adv"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.3329\/bccj.v11i2.69194","article-title":"Effectiveness of plasmapheresis and IVIG in the treatment of Guillain-Barre syndrome: a cross-sectional observational study","volume":"11","author":"Khan MH","year":"2023","unstructured":"Khan MH, Islam MK, Rahman S, et al.. Effectiveness of plasmapheresis and IVIG in the treatment of Guillain-Barre syndrome: a cross-sectional observational study. Bangladesh Crit Care J. 2023, 11:95-102. 10.3329\/bccj.v11i2.69194","journal-title":"Bangladesh Crit Care J"},{"key":"ref14","article-title":"Economic analysis of intravenous immunoglobulin and plasma exchange therapies for the treatment of Guillain-Barr\u00e9 syndrome in a university-based hospital in the south of Brazil","volume":"31","author":"de Brito AP","year":"2011","unstructured":"de Brito AP, Ferreira MA, Maciel PP, Moreira LB. Economic analysis of intravenous immunoglobulin and plasma exchange therapies for the treatment of Guillain-Barr\u00e9 syndrome in a university-based hospital in the south of Brazil. Clin Biomed Res. 2011, 31:275-80.","journal-title":"Clin Biomed Res"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.57066","article-title":"Treatment efficacy of plasmapheresis versus intravenous immunoglobulin in Guillain-Barr\u00e9 syndrome management: a systematic review","volume":"16","author":"Savithri Nandeesha S","year":"2024","unstructured":"Savithri Nandeesha S, Kasagga A, Hawrami C, Ricci E, Hailu KT, Salib K, Butt S. Treatment efficacy of plasmapheresis versus intravenous immunoglobulin in Guillain-Barr\u00e9 syndrome management: a systematic review. Cureus. 2024, 16:e57066. 10.7759\/cureus.57066","journal-title":"Cureus"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1016\/j.ensci.2023.100468","article-title":"Plasma exchange (PE) versus intravenous immunoglobulin (IVIG) for the treatment of Guillain-Barr\u00e9 syndrome (GBS) in patients with severe symptoms: a systematic review and meta-analysis","volume":"31","author":"Zaki HA","year":"2023","unstructured":"Zaki HA, Iftikhar H, Najam M, et al.. Plasma exchange (PE) versus intravenous immunoglobulin (IVIG) for the treatment of Guillain-Barr\u00e9 syndrome (GBS) in patients with severe symptoms: a systematic review and meta-analysis. eNeurologicalSci. 2023, 31:100468. 10.1016\/j.ensci.2023.100468","journal-title":"eNeurologicalSci"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1177\/17562864231154306","article-title":"Comparison of IVIg and TPE efficacy in the treatment of neurological disorders: a systematic literature review","volume":"16","author":"Pinto AA","year":"2023","unstructured":"Pinto AA, De Seze J, Jacob A, Reddel S, Yudina A, Tan K. Comparison of IVIg and TPE efficacy in the treatment of neurological disorders: a systematic literature review. Ther Adv Neurol Disord. 2023, 16:10.1177\/17562864231154306","journal-title":"Ther Adv Neurol Disord"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1111\/tme.12169","article-title":"Comparison on therapeutic effect of plasma exchange and intravenous immunoglobulin for Guillian-Barre syndrome","volume":"25","author":"Ye Y","year":"2015","unstructured":"Ye Y, Li SL, Li YJ. Comparison on therapeutic effect of plasma exchange and intravenous immunoglobulin for Guillian-Barre syndrome. Transfus Med. 2015, 25:79-84. 10.1111\/tme.12169","journal-title":"Transfus Med"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.3233\/RNN-231369","article-title":"Long-term outcomes of plasma exchange versus intravenous immunoglobulin for the treatment of Guillain-Barr\u00e9 syndrome: a double-blind, randomized clinical trial","volume":"41","author":"Haridy NA","year":"2023","unstructured":"Haridy NA, Shehab MM, Khedr EM. Long-term outcomes of plasma exchange versus intravenous immunoglobulin for the treatment of Guillain-Barr\u00e9 syndrome: a double-blind, randomized clinical trial. Restor Neurol Neurosci. 2023, 41:203-17. 10.3233\/RNN-231369","journal-title":"Restor Neurol Neurosci"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1097\/CND.0000000000000119","article-title":"Human immunoglobulin versus plasmapheresis in Guillain-Barre syndrome and myasthenia gravis: a meta-analysis","volume":"18","author":"Ortiz-Salas P","year":"2016","unstructured":"Ortiz-Salas P, Velez-Van-Meerbeke A, Galvis-Gomez CA, Rodriguez Q JH. Human immunoglobulin versus plasmapheresis in Guillain-Barre syndrome and myasthenia gravis: a meta-analysis. J Clin Neuromuscul Dis. 2016, 18:1-11. 10.1097\/CND.0000000000000119","journal-title":"J Clin Neuromuscul Dis"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/297285-evaluating-the-efficacy-and-cost-effectiveness-of-plasmapheresis-and-intravenous-immunoglobulin-in-acute-guillain-barre-syndrome-management-in-emergency-departments","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,29]],"date-time":"2024-10-29T07:02:29Z","timestamp":1730185349000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/297285-evaluating-the-efficacy-and-cost-effectiveness-of-plasmapheresis-and-intravenous-immunoglobulin-in-acute-guillain-barre-syndrome-management-in-emergency-departments"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,29]]},"references-count":20,"URL":"https:\/\/doi.org\/10.7759\/cureus.72595","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,10,29]]}}}